Allergy Diagnostics And Treatment Market Scope
Allergy can be of numerous forms such as asthma, food allergies, rhinitis, conjunctivitis, eczema, urticaria, eosinophilic disorders, drug and insect allergies. The World Allergy Organisation (WAO) assessment of allergy prevalence of the whole population by country ranges between 10 - 40%. Beyond 150 million Europeans suffer from chronic allergic diseases and the current prediction is that by 2025 half of the entire EU population will be affected. The complexity and severity of allergies, especially asthma are on the rise in the young population, who are carrying the largest burden. Rise in the prevalence of allergic diseases and asthma worldwide, especially in developing countries is the main driver for the growth of allergy diagnostics and treatment markets. Urbanization, increase in environmental risk factors such as pollution, smoking, reduced biodiversity are some of the major contributors to the observed upsurge in the prevalence of allergies.
The market study is being classified and major geographies with country level break-up.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Allergy Diagnostics And Treatment market throughout the predicted period.
Alcon Laboratories, Inc. (Switzerland), BioMerieux, Inc. (France), Danaher Corporation (United States), Hitachi Chemical Diagnostics, Inc. (United States), HOB Biotech Group Co., Ltd (China), Hycor Biomedical, Inc. (United States), Lincoln Diagnostics, Inc. (United States), Omega Diagnostics Plc. (United Kingdom), Siemens Healthcare Diagnostic, Inc. (Germany), Stallergenes Greer, Inc. (United Kingdom) and Thermo Fisher Scientific, Inc. (United States) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global Allergy Diagnostics And Treatment market by Type, Application and Region.
On the basis of geography, the market of Allergy Diagnostics And Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On 17 Oct 2019, Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of second-generation COP allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.
- Growing Adoption of Automation for Quicker Turnaround Times
- Growth in the Number of Reagent Rental Agreements
- High Incidence and Large Economic Burden of Allergic Diseases
- Rising Environmental Pollution Levels Have Leads to Various Allergies
- Increasing Healthcare Expenditure across the Globe
- Increasing Access for Allergy Diagnosis Medical Insurance in the United States
- The Emerging Demand from Asia Pacific Region
- Issues Related to the Affordability of Allergy Diagnostics Instruments among Small Laboratories and Physician Clinics
- Lack of Awareness of Allergic Diseases among the People
Key Target AudienceAllergy Diagnostics & Treatment Test Providers, Allergy Diagnostics & Treatment Medications Manufacturers, Regulatory & Government Bodies, Research Institutes, Research & Consulting Firms, End Users, Downstream Vendors and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase